mSphereImmunologyPeer-reviewed journal article
Multi-COBRA hemagglutinin formulated with cGAMP microparticles elicit protective immune responses against influenza viruses
Xiaojian ZhangiD, Hua ShiiD, Dylan A. HendyiD, Eric M. BachelderiD, Kristy M. AinslieiD, Ted M. RossiD
Abstract
Influenza viruses cause a common respiratory disease known as influenza. In humans, seasonal influenza viruses can lead to epidemics, with avian influenza viruses of particular concern because they can infect multiple species and lead to unpredictable and severe disease. Therefore, there is an urgent need for a universal influenza vaccine that provides protection against seasonal and pre-pandemic influenza virus strains. The cyclic GMP-AMP (cGAMP) is a promising adjuvant for subunit vaccines that promotes type I interferons production through the stimulator of interferon genes (STING) pathway. The encapsulation of cGAMP in acetalated dextran (Ace-DEX) microparticles (MPs) enhances its intracellular delivery. In this study, the Computationally Optimized Broadly Reactive Antigen (COBRA) methodology was used to generate H1, H3, and H5 vaccine candidates. Monovalent and multivalent COBRA HA vaccines formulated with cGAMP Ace-DEX MPs were evaluated in a mouse model for antibody responses and protection against viral challenge. Serological analysis showed that cGAMP MPs adjuvanted monovalent and multivalent COBRA vaccines elicited robust antigen-specific antibody responses after a prime-boost vaccination and antibody titers were further enhanced after second boost. Compared to COBRA vaccine groups with no adjuvant or blank MPs, the cGAMP MPs enhanced HAI antibody responses against COBRA vaccination. The HAI antibody titers were not significantly different between cGAMP MPs adjuvanted monovalent and multivalent COBRA vaccine groups for most of the viruses tested in panels. The cGAMP MPs adjuvanted COBRA vaccines groups had higher antigen-specific IgG2a binding titers than the COBRA vaccine groups with no adjuvant or blank MPs. The COBRA vaccines formulated with cGAMP MPs mitigated disease caused by influenza viral challenge and decreased pulmonary viral titers in mice. Therefore, the formulation of COBRA vaccines plus cGAMP MPs is a promising universal influenza vaccine that elicits protective immune responses against human seasonal and pre-pandemic strains.
- organism: mouse
- research focus: host-pathogen & immune response
- research focus: drug response / drug discovery
- approach: experimental assay
- Citations
- 10
- FWCI
- 3.01
- Field percentile
- top 9%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A Single Dose of Inactivated Influenza Virus Vaccine Expressing COBRA Hemagglutinin Elicits Broadly-Reactive and Long-Lasting Protection
Hua Shi, Xiaojian Zhang, Ted M. Ross·PLoS ONEPeer-reviewed·Feb 21, 2025
- Computationally Optimized H1 and H3 Hemagglutinin Messenger RNA Vaccines Confer Broad Protective Immunity Against Modern Influenza Viruses
James D. Allen, Jessica M. Medina, … Ted M. Ross·bioRxiv·Sep 10, 2026
- Antigenic landscape analysis of individuals vaccinated with a universal influenza virus vaccine candidate reveals induction of cross-subtype immunity
P. S. Meade, S. Strohmeier, … F. Krammer·bioRxiv·Jul 6, 2022
- Elicitation of broadly protective immunity to influenza by multivalent hemagglutinin nanoparticle vaccines
S. Boyoglu-Barnum, D. Ellis, … M. Kanekiyo·bioRxiv·May 30, 2020
- A Universal, Single-Component Multilayered Self-Assembling Protein Nanoparticle Vaccine Based on Extracellular Domains of Matrix Protein 2 Against Both Influenza A and B
Yi-Nan Zhang, Keegan Braz Gomes, … Jiang Zhu·VaccinesPeer-reviewed·Aug 28, 2024
- Intranasal hemagglutinin protein boosters induce robust mucosal immunity and cross-protection against influenza A viral challenge
Miyu Moriyama, Gisele Regina Rodrigues, … Akiko Iwasaki·Proceedings of the National Academy of SciencesPeer-reviewed·Sep 24, 2025